Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK565977PMID: 33355740
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 928134-65-0
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of osilodrostat during breastfeeding. Because of the potential for serious adverse reactions, such as adrenal insufficiency, in the breastfed infant, breastfeeding is not recommended during treatment with osilodrostat and should be avoided until 1 week after the final dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Osilodrostat
CAS Registry Number
928134-65-0
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats.[Toxicol Appl Pharmacol. 2015]Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats.Li L, Vashisht K, Boisclair J, Li W, Lin TH, Schmid HA, Kluwe W, Schoenfeld H, Hoffmann P. Toxicol Appl Pharmacol. 2015 Aug 1; 286(3):224-33. Epub 2015 May 14.
- Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.[Pituitary. 2016]Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.Fleseriu M, Pivonello R, Young J, Hamrahian AH, Molitch ME, Shimizu C, Tanaka T, Shimatsu A, White T, Hilliard A, et al. Pituitary. 2016 Apr; 19(2):138-48.
- Osilodrostat oral tablets for adults with Cushing's disease.[Expert Rev Endocrinol Metab. 2...]Osilodrostat oral tablets for adults with Cushing's disease.Martino M, Aboud N, Lucchetti B, Salvio G, Arnaldi G. Expert Rev Endocrinol Metab. 2022 Mar; 17(2):99-109. Epub 2022 Feb 28.
- Review Osilodrostat: A Review of Recent Clinical Studies and Practical Recommendations for its Use in the Treatment of Cushing Disease.[Endocr Pract. 2021]Review Osilodrostat: A Review of Recent Clinical Studies and Practical Recommendations for its Use in the Treatment of Cushing Disease.Yuen KCJ. Endocr Pract. 2021 Sep; 27(9):956-965. Epub 2021 Aug 10.
- Review Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.[Drug Des Devel Ther. 2023]Review Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.Perosevic M, Tritos NA. Drug Des Devel Ther. 2023; 17:1303-1312. Epub 2023 Apr 27.
- Osilodrostat - Drugs and Lactation Database (LactMed®)Osilodrostat - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...